Double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of ABT-925 in subjects with acute exacerbation of schizophrenia
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2011
At a glance
- Drugs ABT 925 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 14 Dec 2007 Status changed from recruiting to discontinued according to ClinicalTrials.gov.
- 16 Apr 2007 New trial record.